IMMUNOHISTOCHEMICAL EXPRESSION PATTERNS OF P53 IN SURFACE EPITHELIAL OVARIAN TUMORS - A DESCRIPTIVE STUDY IN CENTRAL KERALA
Main Article Content
Keywords
Epithelial Ovarian Tumors, high Grade Serous Carcinoma, IHC, p53
Abstract
Introduction: Although there have been significant advancements in the treatment of gynaecological malignancies, ovarian tumors continue to be the most deadly. The current study aims to evaluate p53 expression in different types & histological grades of epithelial ovarian tumors (EOT) by means of immunohistochemistry (IHC).
Material & Methods: In the present descriptive study, the 50 epithelial ovarian tumors specimen received at department of pathology during the period of two year were chosen for the research. Parameters such as capsule rupture, ascites, tumor size, metastasis, stage at presentation & tumor grade were correlated.
Results: Of the fifty EOT instances, twenty (40%) were malignant, five (10%) were borderline, & twenty (50%) were benign. With 24 cases (48%), serous tumors constituted the majority. With 14 instances (70%) of serous malignancies, the largest group was made up of 3 cases (15%) of mucinous malignancies, 2 cases (10%) of endometrioid carcinoma, & 1 case (5%), of clear cell carcinoma. Every benign & borderline EOT had a wild type or p53 negative result. Of the 20 malignant tumors, 14 (or 70%) were serous malignancies & p53 positive. 20% of HGSC & LGSC displayed aberrant null staining, whereas 73.4% of them displayed widespread p53 staining. There were positive relationships between P53 staining & CA 125, ascites, & capsule rupture.
Conclusion: The research emphasizes how varied p53 expression rates & staining patterns exist, & how accurate p53 IHC interpretation is essential for the diagnosis of distinct EOT.
References
2. Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: Recent concepts on its origin & carcinogenesis. J Hematol Oncol 2012;5:8.
3. Seidman JD, Horkayne Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type & stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41 4.
4. National cancer registry programme. Indian council of medical research Time trends in cancer incidence rates 1982-2010; Chapter 4 Trends Over Time for All Sites & on Selected Leading Sites of Cancer.
5. Phukan A, Borgogoi M, Ghosh S. Histopathological spectrum of ovarian tumors: an institutional perspective. Int. J Res Med Sci 2018;6:2639-43.
6. Swarnalatha P, Reddy SR, Chaitanya B. Study of histomorphological spectrum of ovarian neoplasms: an institutional perspective. International Journal of Advances in Medicine 2019;6(5):1563-6.
7. Ren YA, Mullany LK, Liu Z, Herron AJ, Wong KK, Richards JS. Mutant p53 promotes epithelial ovarian cancer by regulating tumor differentiation, metastasis, & responsiveness to steroid hormones. Cancer Res 2016;76(8):2206-18.
8. Sreeja TT, Chandrasekhar S, Magar SLR, Durga K, Rani HS, Anil SS. A study on expression of p53 in surface epithelial ovarian tumors. Indian Journal of Mednodent & Allied Sciences 2015;3(1)1:18-25.
9. Naik PS, Deshmukh S, Khandeparkar SG, Joshi A, Babanagare S, Potdar J, et al. Epithelial ovarian tumors: Clinicopathological correlation & immunohistochemical study. J Midlife Health 2015;6:178-83.
10. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609 15.
11. Scully RE. International Histological Classification of Tumors: Histological Typing of Ovarian Tumors. 2nd edition. Heidelberg: Springer-Verlag 1998
12. Fathalla MF. Factors in the causation & incidence of ovarian cancer. Obstetrical &Gynecological Survey 1972;27(11):751-68.
13. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609.
14. Amanullah NA, Poothiode U, Vilasiniamma L. Expression of p53 in epithelial ovarian tumors. Indian J Pathol Microbiol 2020;63:235-40.
15. Modest effect of p53, EGFR & HER 2/neu on prognosis in epithelial ovarian cancer: a meta analysis. Br J Cancer 2009;101:149 59.
16. Zheng J, Benedict WF, Xu HJ, Hu SX, Kim TM, Velicescu M, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas & solitary cystadenomas. J Natl Cancer Inst 1995;87:1146 53.
17. Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her 2 neu, p53 & Ki 67 in epithelial ovarian tumors & its correlation with clinicopathologic variables. Indian J Pathol Microbiol 2012;55:33 7.
18. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003;91:504 12.
19. Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, et al. Prognostic significance of p53 mutation & p53 overexpression in advanced epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncology 2003;21:3814 25.
20. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation & expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004;93:301 6.
21. Chiesa Vottero AG, Malpicia A, Deavers MT, Broaddus R, Nuevo GJ, Silva EG. Immunohistochemical overexpression of p16 & p53 in uterine serous carcinoma & ovarian high grade serous carcinoma. Int J Gynecol Pathol 2007;26:328 33.
22. Bilyk OO, Pande NT, Buchynska LG. Analysis of p53, p16(INK4a), pRb & Cyclin D1 expression & human papillomavirus in primary ovarian serous carcinomas. Exp Oncol 2011;33:150 6.
23. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical & nucleotide sequencing analysis. Mod Pathol 2011;24:1248 53.
24. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-16.
25. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller C. The fallopian tube: Primary site of most pelvic high grade serous carcinomas. Int J Gynecol Cancer 2009;19:58 64.
26. Angelopoulou K, Rosen B, Stratis M, Yu H, Solumou M, Diamandis EP. Circulating antibodies against p53 protein in patients with ovarian carcinoma correlation with clinicopathological factors & survival. Cancer 1996;78.
27. Häfner N, Nicolaus K, Weiss S, Frey M, Diebolder H, Rengsberger M, et al. p53 autoantibody may be more sensitive than CA 125 in monitoring microscopic & macroscopic residual disease after primary therapy for epithelial ovarian cancer. J Cancer Res Clin Oncol 2013;139:1207 10.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Aswathi R.
Assistant Professor, Department of Pathology, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, India.
Dr. Jayalakshmi S.
Junior Resident, Department of Pathology, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, India.